Which statement is NOT true regarding the hyperosmotic agent Glycerine (Osmoglyn)?

Glycerine, commonly known as Osmoglyn, is administered orally as a hyperosmotic agent primarily to reduce intraocular pressure in conditions like glaucoma. However, the statement that it is administered orally is true, making the claim that this is the incorrect statement misleading.

The correct understanding of the statement regarding the high molecular weight of glycerine pertains to its pharmacological action. Glycerine does indeed have a high molecular weight, which prevents it from crossing the blood-aqueous barrier significantly, thus limiting its effect within the immediate intraocular environment but still allowing it to exert its osmotic effect systemically.

Additionally, it is well-documented that glycerine can cause gastrointestinal discomfort, and many patients experience nausea and vomiting as a common side effect when ingesting this hyperosmotic agent. Furthermore, glycerine is known to raise blood glucose levels, which makes it unsuitable for diabetic patients who are concerned about hyperglycemia.

In summary, the statements about the side effects of glycerine, its characteristics related to the blood-aqueous barrier, and its effect on diabetic patients are all accurate. Therefore, the claim regarding the oral administration being the false statement does not hold, as it is indeed administered orally.